超越COVID，结核病再次成为单一传染病导致死亡的主要原因

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL Journal of Medicinal Chemistry Pub Date : 2024-12-09 DOI:10.1021/acs.jmedchem.4c02876

Tomayo Berida, Craig W. Lindsley

{"title":"超越COVID，结核病再次成为单一传染病导致死亡的主要原因","authors":"Tomayo Berida, Craig W. Lindsley","doi":"10.1021/acs.jmedchem.4c02876","DOIUrl":null,"url":null,"abstract":"Figure 1. Antitubercular drugs in clinical use. (3,4) Table one was adapted from WHO’s 2023 Antibacterial agents in clinical and preclinical development. (16) NCR: No cross resistance, NCC: New chemical class; NT: New target; MoA: New mechanism of Action. Figure 2. Antitubercular agent in clinical development. Figure 3. Cell wall of mycobacteria (left), Gram-positive bacteria (center), and Gram-negative bacteria (right). The figure was adapted from “Plant Antibacterials: The Challenges and Opportunities”, Berida et al, Heliyon 2024, 10 (10), e31145, with permission from Elsevier. (26) This article references 38 other publications. This article has not yet been cited by other publications.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"20 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Move over COVID, Tuberculosis Is Once again the Leading Cause of Death from a Single Infectious Disease\",\"authors\":\"Tomayo Berida, Craig W. Lindsley\",\"doi\":\"10.1021/acs.jmedchem.4c02876\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Figure 1. Antitubercular drugs in clinical use. (3,4) Table one was adapted from WHO’s 2023 Antibacterial agents in clinical and preclinical development. (16) NCR: No cross resistance, NCC: New chemical class; NT: New target; MoA: New mechanism of Action. Figure 2. Antitubercular agent in clinical development. Figure 3. Cell wall of mycobacteria (left), Gram-positive bacteria (center), and Gram-negative bacteria (right). The figure was adapted from “Plant Antibacterials: The Challenges and Opportunities”, Berida et al, Heliyon 2024, 10 (10), e31145, with permission from Elsevier. (26) This article references 38 other publications. This article has not yet been cited by other publications.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.4c02876\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02876","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

图1所示。抗结核药物的临床应用。（3,4）表1改编自世卫组织《2023年临床和临床前开发中的抗菌药物》。（16） NCR：无交叉抗性，NCC：新化学类；NT：新目标；答：新的作用机制。图2。临床开发中的抗结核药物。图3。分枝杆菌细胞壁（左），革兰氏阳性菌（中），革兰氏阴性菌（右）。该图改编自Berida等人的《植物抗菌剂：挑战与机遇》，Heliyon 2024, 10 (10), e31145，经爱思唯尔许可。（26）本条参考了其他38份出版物。这篇文章尚未被其他出版物引用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Move over COVID, Tuberculosis Is Once again the Leading Cause of Death from a Single Infectious Disease

Figure 1. Antitubercular drugs in clinical use. (3,4) Table one was adapted from WHO’s 2023 Antibacterial agents in clinical and preclinical development. (16) NCR: No cross resistance, NCC: New chemical class; NT: New target; MoA: New mechanism of Action. Figure 2. Antitubercular agent in clinical development. Figure 3. Cell wall of mycobacteria (left), Gram-positive bacteria (center), and Gram-negative bacteria (right). The figure was adapted from “Plant Antibacterials: The Challenges and Opportunities”, Berida et al, Heliyon 2024, 10 (10), e31145, with permission from Elsevier. (26) This article references 38 other publications. This article has not yet been cited by other publications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.